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ABSTRACT
Background & objectives: Chloroquine (CQ), followed by 14-day primaquine, is the recommended regimen for
the treatment of Plasmodium vivax infection in Thailand. CQ resistant P. vivax (CRPv) has not yet challenged
the efficacy of the drug. The present study was conducted to assess the current response of P. vivax to CQ alone
in Thailand.
Methods: A 28-day in vivo therapeutic efficacy study was conducted from June 2009 to December 2010 in 4
sentinel sites. Recurrence of parasitaemia and the clinical condition of patients were assessed on each visit
during follow-up. The drug levels in recurrent patients’ blood were measured using HPLC. Data were analyzed
using the WHO 2008 program for the analysis of in vivo tests.
Results: Of the total 212 patients included in the study, 201 completed the 28-days follow-up, while 11 were
excluded. In five patients (2.5%), parasitaemia reappeared within the 28-days follow-up. On the day of recurrent
parasitaemia, the level of chloroquine/desethylchloroquine (CQ-DCQ) was above the minimum effective
concentration (>100 ng/ml) in one patient, but lower in four patients.
Conclusion: Reappearance of the parasite within 28 days of follow-up in one of five patients was due to parasite
resistance to CQ. The 2.5% prevalence of CQ treatment failure for P. vivax malaria in the study areas signals the
need to launch monitoring activities for CQ resistant P. vivax in malaria endemic areas in order to detect further
development of parasite resistance and to estimate the level of burden across the country.
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INTRODUCTION
In Thailand, malaria transmission is seasonal and
unstable, causing frequent epidemics. The two species,
Plasmodium falciparum and P. vivax, most commonly
cause malaria in Thailand. The proportion of P. vivax to
P. falciparum in Thailand increased from 49.3% in 2007
to 58.2% in 20101.
Resistance to antimalarial drugs in P. falciparum is
well-recorded in Thailand but is not well-known for P.
vivax.  A single study in 2011 reported relapsing and chlo-
roquine-resistant P. vivax (CRPv) in a Karen pregnant
woman from the refugee camp in Tak2.  A 3-day regimen
of chloroquine (CQ) followed by 14-days primaquine re-
mains as the first-line treatment of P. vivax infection
throughout the country. However, CRPv has been emerg-
ing in different parts of the world3.
The present study is part of the routine monitoring for
efficacy of antimalarial drugs against P. falciparum and
P. vivax in the country. It was conducted in 4 provinces:
Mae Hong Son, Kanchanaburi, Yala, and Chanthaburi,
during 2009 and 2010.
MATERIAL & METHODS
This study was registered with the Australia-New
Zealand Clinical Trials Registry (ANZCTR) No: ACTRN
12610000554066. 191 Congpuong et al: Vivax malaria in Thailand
Study area
The study was conducted at four sentinel sites situ-
ated in Pong Nam Ron district, Chanthaburi province (east-
ern border with Cambodia) and Bannansatar district, Yala
province (southern border with Malaysia) during June–
November 2009, and in Maung and Sob Moey districts in
Mae Hong Son province (north-western border with
Myanmar) and Saiyok district, Kanchanaburi province
(central-western border with Myanmar) during June–De-
cember 2010 (Fig. 1). Malaria patients were both Thai
and non-Thai. The majority was male adults and had ag-
ricultural and forest-related occupations. The climate is
typically tropical with a rainy season extending from May/
June to November. The annual parasite incidences (APIs)
in 2010 for malaria were 1.60, 5.61, 8.34 and 4.32 per
1,000 population in Chanthaburi, Yala, Mae Hong Son
and Kanchanaburi, respectively1.
Patients
Clinically suspected patients seeking medication at
malaria clinics in the study sites were examined for the
presence of P. vivax infection on thick blood film prepara-
tions. Among the screened patients, those who fulfilled
the inclusion criteria set by WHO4 were recruited for the
28-days in vivo study. Inclusion criteria were: uncompli-
cated P. vivax mono-infection with parasitaemia between
250 and 100,000 parasites/μl of blood; age >6 months;
axillary temperature >37.5°C or a history of fever in the
past 24 h; informed consent from patient or parent/guard-
ian (in the case of children); and ability to attend the stipu-
lated follow-up visits. Exclusion criteria were: inability to
drink or feed; repeated vomiting, convulsions during the
present illness; inability to sit or stand up; presence of a
severe disease; presence of severe malnutrition; pregnancy
and any febrile disease other than malaria.
Treatment and follow-up
The in vivo tests were performed according to the
WHO guidelines4. The patients were treated with a 25
mg/kg chloroquine, administered for 3 consecutive days
(15 mg/kg loading dose divided into 3 meals on Day 0 and
5 mg/kg daily on Day 1 and Day 2).
Successive monitoring of the parasitological and clini-
cal responses overtime was conducted for 28 days. The in
vivo testing was conducted with the purpose of determin-
ing the parasite clearance time (PCT), defined as the time
from the start of chloroquine treatment until blood films
became negative. All doses were administered under di-
rect observation. Physiological complains were recorded
at the time of each visit. Subjects were checked for vomit-
ing for 30 min after ingestion of the drug; those who vom-
ited were re-treated with an identical dose provided that
the subject vomited the entire ingested drug. Subjects who
vomited twice were dropped from the study. The study
participants were advised not to take other drugs, except
for patients with axillary temperature > 37.5°C who were
treated with paracetamol. 
Patients were asked to return for follow-up on Days
1, 2, 3, 7, 14, 21 and 28, and on any occasion of malaria
like illness, for clinical examination including recording
of temperature. Thick blood smears were prepared at all
follow-up visits. 100 μl of blood sample was collected on
filter paper using heparinized capillary tube from lancet
pricked finger on Days 0, 7, 28 and any day when patients
had recurrent parasitaemia for measurement of whole blood
chloroquine (CQ) and desethylchloroquine (DCQ) con-
centrations.
Patients who did not come for follow-up were traced
to their homes. After completion of the follow-up, all pa-
tients were given 15 mg primaquine daily for 14 consecu-
tive days. Those who failed to respond to CQ were re-
treated with 25 mg/kg chloroquine plus primaquine
according to the national treatment guidelines.
Parasite identification
Parasites were identified by microscopic examination
of morphology using thick blood smears taken at enrol-
ment (Day 0). Subsequently, blood slides were taken at Fig. 1: Map of Thailand showing the study sites
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following visits (scheduled and non-scheduled). Smears
were stained with Giemsa (3%, pH 7.2) for 45 min, and
thick films were examined for malaria parasites under oil-
immersion. Plasmodium vivax asexual stages were counted
against 200 white blood cells (WBCs) or 500 WBC, if the
number of asexual parasites was below 10 per 200 WBC,
assuming the mean total WBC count of 6000/μl for the
study population.  WHO4 recommended white blood cell
density of normal subject, typically 6000–8000/μl. How-
ever, WBC counts in malaria patients were lower than in
normal subjects. The median values for WBC counts of Thai
malaria patients were in the range of 5900–7100/μl5.
Gametocytes were counted, based on the same mean WBC
count of 6000/μl.  Experienced laboratory technicians
working in the malaria clinic examined each blood smear.
All the slides were re-examined by an expert microscopist
at the Reference Laboratory of the Bureau of Vector Borne
Disease.
Endpoints
Treatment efficacy was determined based on the WHO
classification of treatment outcome4 as follows: (i) early
treatment failure (ETF); (ii) late clinical failure (LCF);
(iii) late parasitological failure (LPF); and (iv) adequate
clinical and parasitological response (ACPR).
Recurrence denoted clinical and parasitological recur-
rence of malaria after the initial clearance of parasite from
circulation. In the per protocol analysis, the proportion of
treatment failures was calculated by dividing the number
of subjects with recurrent parasitaemiae by the total num-
ber of subjects who either suffered recurrent parasitaemia
or completed the full 28-day follow-up period. In the
Kaplan-Meier analysis, subjects were censored from the
point at which they were either lost to follow-up or showed
infection by P. falciparum. Subjects were considered to
have cleared parasitaemia if there were at least two se-
quential negative smears. The day on which the first such
negative smear was observed was defined as the day of
clearance. This study was done in out-patient malaria clin-
ics. Thick blood smear was examined daily on Day 0, 1,
2, 3 and during the follow-up visit on Day 7, 14, 21 and
28. Daily parasite counting limited the possibility to cal-
culate the true PCT. Because smears were not taken on
days 4–6, subjects with a reported clearance on Day 7
may actually have cleared their parasitaemia on any day
between 4 and 7.
When failure occurred in the presence of blood chlo-
roquine concentrations (CQ + DCQ) > 100 ng/ml, the re-
appeared parasite should be considered resistant to CQ
irrespective of its genotype (relapse, recrudescence or re-
infection)6.
Chloroquine (CQ) and desethylchloroquine (DCQ) lev-
els in whole blood
CQ and DCQ were assayed using solid-phase extrac-
tion and high-performance liquid chromatography (HPLC)
with UV detector7. The mobile phase was 5:95 acetoni-
trile/100 mM phosphate buffer, with a flow rate of 1 ml/
min through a CN column.  The UV detection was set at
342 nm. The dried blood spots were cut into small pieces
and CQ and DCQ were extracted using solid-phase ex-
traction. Eluates were evaporated to dryness at 70°C un-
der a stream of air, then reconstituted in 100 μl mobile
phase and 50 μl of sample was injected into LC-system.
The assays were linear over the ranges of 30–14,600 ng/
ml for chloroquine and desethylchloroquine.
Data analysis
Data collected from in vivo therapeutic efficacy study
were double entered and analyzed using WHO program
for the in vivo therapeutic efficacy study. Kaplan-Meier
survival probability analysis was used to evaluate treat-
ment outcome of study participants during follow-up pe-
riod. Parasite clearance time and gametocyte clearance
time of parasites from four sentinel sites were compared
using Log Rank (Mantel-Cox) in the Kaplan-Meier analy-
sis.  In non-normally distributed data, the median was used
to measure the central tendency. In all analysis, p-values
< 0.05 were considered significant.
Ethical clearance
The study was reviewed and approved by the Ethical
Review Committee of the Department of Disease Control,
Ministry of Public Health, Thailand. Written informed
consent was obtained from each patient or guardians par-
ents, in cases when the study subjects were younger than
18 yr. Written informed accent was also obtained from
each patient between 15 and 17 yr.
RESULTS
Characteristics of the study population
A total of 212 patients who met all the inclusion crite-
ria were enrolled at four sentinel sites. Characteristics of
the study population are shown in Table 1. The majority
of patients were adults over 15 yr (81.1%) and males
(72.2%). The median age was 25 yr (range = 2–80 yr),
but was statistically different at the four sentinel sites
(p = 0.001). The highest median age was in Mae Hong
Son (30.5), followed by Kanchanaburi (27), Chanthaburi
(24) and Yala (19). The proportions of male and female
subjects in the four sentinel sites were not statistically dif-
ferent (p >0.05). About 80% were males in Mae Hong 193 Congpuong et al: Vivax malaria in Thailand
Son, 75% in Kanchanaburi, 72.7% in Chanthaburi and
60.4% in Yala.
Of the total 212 cases included in the study, 11 cases
(5.2%) were excluded from the analysis: one had P.
falciparum on Day 7 and was re-treated with artesunate-
mefloquine combination; 10 cases were lost to follow-up
on Day 3 (2 cases), Day 7 (2 cases), Day 14 (2 cases),
Day 21 (1 case) and Day 28 (3 cases). A total of 201
cases completed the study and were included in per proto-
col analysis.
The geometric mean (GM) of parasite density on the
Day of enrolment was 4586 parasites/μl (95% CI = 3961–
5309). Patients in Chanthaburi had the highest GM para-
site density (7614) which was statistically different from
the other provinces (p=0.001). The GM parasite density
of the other 3 provinces, Mae Hong Son (3879),
Kanchanaburi (3757) and Yala (3874) were not statisti-
cally different (p >0.05).
Most of the study participants, 88.2% (n = 187), were
febrile, axillary temperature >37.5°C on the Day of en-
rolment. The percentage declined to 37.3, 16.5, and 4.3%
on Days 1, 2, and 3, respectively. All remained afebrile
on follow-up. The mean body temperature on the Day of
enrolment was 38.5°C (95% CI = 38.3–38.6) (Table 1).
Treatment response
Mean parasite clearance time (MPCT) analyzed by
Kaplan-Meier analysis was 2.1 days. Parasite clearance
was achieved within 1 day in 41.5%, 2 days in 34.4% and
3 days in 16.1% of study participants. Complete parasite
clearance was achieved on Day 7 in the remaining 8%.
Figure 2 shows time to parasite clearance plot against time
after initiation of treatment. Clearance time in Chanthaburi
was significantly longer compared to the other sites
(p <0.0001). The MPCT was 3.7 days compared to 2 days
in Mae Hong Son, 1.6 days in Kanchanaburi, and 1.1 days
in Yala. In Chanthaburi, a high proportion of patients
(27.3%) maintained parasitaemia until Day 7.
Approximately, 80% of vivax malaria patients in this
study presented with gametocytaemia. The geometric mean
gametocytaemia on the enrolment day was 156 gameto-
cytes/μl blood (95% CI = 133–183). Patients in
Chanthaburi province statistically had the highest
gametocytaemia (325 gametocytes/μl blood) (Table 2).
Figure  3 shows the time to gametocyte clearance plot
against time after initiation of treatment. Mean Gameto-
cyte clearance time (MGCT) was 1.9 days. The MGCT
of Yala was significantly shorter than the other provinces
(p <0.0001). It was 1.1 days compared to 2.2, 2.3 and 1.8
Table 2. Presence and geometric mean of  P. vivax gametocytes on Day of enrolment in Mae Hong Son, Kanchanaburi,
Chanthaburi and Yala provinces
Province No. samples Presence of gametocytes on Day 0 (%)            GM gametocyte/μl
Mae Hong Son 56 40 (71.4) 114  (95% CI, 87–149)
Kanchanaburi 48 42 (87.5) 103 (95% CI, 77–137)
Yala 53 43 (81.1) 146 (95% CI, 120–178)
Chanthaburi 55 45 (81.8) 325 (95% CI, 228–462)
Total 212 170 (80.2) 156 (95% CI, 133–183)
Table 1. Demographic and clinical characteristics of the study participants
Characteristics at day of Total Mae Kanchanaburi Chanthaburi Yala
admission (Day 0) Hong Son
Sample size 212 56 48 55 53
Median age (yr, range) 25 (2–80) 30.5 (12–66) 27 (7–71) 24 (9–80) 19 (2–68)
Sex
Male (%) 153 (72.2) 45 (80.4) 36 (75) 40 (72.7) 32 (60.4)
Female (%) 59 (27.8) 11 (19.6) 12 (25) 15 (27.3) 21 (39.6)
Mean body temperature 38.5°C 38.9°C 37.9°C 38.3°C 38.5°C
     (95% CI) (38.3–38.6) (38.7–39.2) (37.7–38.1) (38–38.7) (38.3–38.7)
Febrile–axillary Temp. > 37.5°C (%) 187 (88.2) 55 (98.2) 43 (89.6) 39 (70.9) 50 (94.3)
Geometric mean parasite 4586 3879 3757 7614 3874
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days of Chanthaburi, Mae Hong Son and Kanchanaburi,
respectively.
Among patients who completed follow-up and were
treated with CQ under supervision at the therapeutic dose,
5 of 201 had recurrent parasitaemia within the 28 days
follow-up (1, 1, and 3 on Days 14, 21, and 28, respec-
tively). Three patients cleared parasites on Day 1 while
the other two cleared on Day 3. According to the WHO
criteria, all were classified as LPF. The 28-day cure rate
or ACPR according to per protocol analysis was 97.5%
(196/201). ACPR in Mae Hong Son, Kanchanaburi,
Chanthaburi, and Yala were 100% (49/49), 93.8%
(45/48), 96.1% (49/51), and 100% (53/53), respectively.
Table 3 shows the life table estimation of interval risk and
cumulative risk of recurrent parasitaemia.
CQ-DCQ level in patients with treatment success or failure
In 24 patients (5 treatment failures and 19 successful
treatment) with  measured CQ and DCQ drug levels, me-
dian (and range) of whole blood levels of CQ and its ma-
jor metabolite, DCQ after initiation of therapy on Day 0,
7 and 8 were 0 (0–2618), 725 (442–3423) and 78 (0–
2114), respectively (Fig. 4).
CQ-DCQ was detected on Day 0 in 3 of 5 patients
Fig. 2: Time to parasite clearance plot against time after initiation of
treatment. Mean time to parasite clearance of Yala = 1.1 days
(n = 53), Chanthaburi = 3.7 days (n = 55), Mae Hong Son =
2.0 days (n = 56), Kanchanaburi = 1.6 days (n = 48), Total =
2.1 days; Log Rank (Mantel Cox) p < 0.0001; YL: PCT  = 1.1
days; CB  PCT  = 3.7 days; MH PCT  = 2.0 days; KN PCT   =
1.6 days.
Fig. 3: Time to gametocyte clearance plot against time after initiation
of treatment. Mean time to gametocyte clearance of Yala =
1.1 days (n = 43), Chanthaburi = 2.2 days (n = 45), Mae
Hong Son = 2.2 days (n = 40), Kanchanaburi = 1.8 days,
Total = 1.9 days (n = 42); Log Rank (Mantel Cox) p < 0.0001;
YL: GCT  = 1.1 days; CB  GCT  = 2.2 days; MH GCT  = 2.2
days; KN GCT   = 1.8 days.
Table 3. Life table estimation of cumulative incidence (risk) of recurrent parasitaemia after chloroquine therapy of vivax malaria in four
provinces of Thailand in 2009 and 2010
Days No. of subjects No. of subjects No. of cases Interval risk Cumulative risk
remaining at withdrawn due to of therapeutic  (IR)  (CR)
risk (N)   any reason (w) failure (i)
Day 0 212 0 0 0 0
Day 1 212 0 0 0 0
Day 2 212 2 0 0 0
Day 3 210 3 0 0 0
Day 7 207 2 0 0 0
Day 14 205 1 1 0.005 0.005
Day 21 203 6 1 0.005 0.010
Day 28 196 193 3 0.015 0.025
Note: Interval risk was calculated as follows: i = [N – (w/2)]
-1, where N is the number of subjects remaining at risk, i  is the number of cases
of therapeutic failure, and w is the number of subjects withdrawn for any reason. The cumulative incidence of therapeutic failure (CR
n) was
calculated as follows: CR
n = 1 – [(1 – IR
n)  (1 – CF
n-1)], where, IR is interval risk, n is the day of the test, and n-1 is the prior interval. To
calculate the CR for Day 21, first estimate the interval risk as follows: 1[1– (2/2)
-1 = 0.0054] and, finally, 1 – [(1–0.0054)  (1–0.0054)] =
0.0102. Thus, the 21-day cumulative incidence (or risk) of therapeutic failure was 1%. 195 Congpuong et al: Vivax malaria in Thailand
with treatment failure, suggesting they were exposed to
CQ before the start of treatment. All patients with treat-
ment failure were found capable of absorbing the deliv-
ered CQ as confirmed by the detection of a high blood
concentration of CQ on Day 7. One patient had CQ/DCQ
above the minimum effective concentration (MEC) on the
day of recurrent parasitaemia.  This patient was then clas-
sified as CRPv case.  The remaining four patients had a
lower CQ/DCQ level than the MEC (100 ng/ml).
The distribution of CQ+DCQ concentration on Day
28 was abnormal; the median drug concentration was 78
ng/ml (range 0–2114). Fourteen of the 24 patients whose
blood was measured had CQ+DCQ concentration below
the MEC (100 ng/ml). These comprised 4 recurrent pa-
tients and 10 successful treatment patients.
Safety and tolerability
No serious adverse events (SAE) were reported dur-
ing the study. Many adverse events (AE) such as head-
ache, muscle pain and anorexia were most likely related
to the underlying malaria disease. These symptoms disap-
peared by Day 2 or 3 after treatment.
DISCUSSION
Chloroquine, the first antimalarial drug in Thailand,
was used to treat both uncomplicated falciparum and vivax
malaria since 1945. Plasmodium falciparum has devel-
oped resistance to various antimalarial drugs, resulting in
several changes of drug policy, i.e. sulfadoxine-py-
rimethamine (in 1973), mefloquine-sulfadoxine-py-
rimethamine (1983), and mefloquine alone (1991). Cur-
rent first line treatment has been a combination of
artesunate-mefloquine since 1995. Treatment of P. vivax
by chloroquine, on the contrary, has remained effective8–10.
However, there was a recent report of chloroquine resis-
tant P. vivax in a pregnant woman in Tak province of
Thailand2.
Pre-treatment with CQ in the study areas was com-
mon as observed from the  presence of CQ+DCQ. From
24 patients whose blood was measured, 10 had detectable
CQ+DCQ. These patients may have treated themselves
with available CQ drug from the markets.  CQ is not a
controlled drug because it was available before 1985 when
the antimalarial drug policy for controlling drugs in Thai-
land was launched. It is also possible that these patients
had recurrence of parasites from relapse, re-infection or
recrudescence when drug from the previous treatment was
still present.
Measurement of drug levels from finger-prick blood
dropped onto the filter papers results in lower drug levels
compared to the method measuring from venous whole
blood11,12. This is in part due to the lower yield of the
extraction method and the dilution of blood by the inter-
stitial fluid during blood collection from finger prick. Blood
collection on filter paper is feasible in areas where labora-
tory facilities are inadequate. However, drug concentra-
tion measurement from blood collected on filter paper
should be standardized. The minimum effective concen-
tration (MEC) of CQ+DCQ against P. vivax is 90–100
ng/ml of whole blood13. Because of the wide use of finger-
prick blood collected on filter paper, the MEC should be
set for the measurement of CQ+DCQ from filter paper.
Because a patient in Chanthaburi recurrent on Day
14 with low parasitaemia (12 parasites/μl) was not de-
tected by the microscopist in the field, no blood was col-
lected for measuring chloroquine drug level on that day.
The detected parasites were suspected to be hypnozoites
and were likely eliminated by the remaining CQ+DCQ in
the blood such that no parasites were detected on Day 21
and Day 28. The CQ+DCQ concentration in the blood of
this patient was 576 ng/ml and 34 ng/ml on Day 21 and
Day 28, respectively.
This study was done in four sentinel sites located in
different parts of the country. It is well-known that P.
falciparum malaria in different parts of Thailand has dif-
ferent sensitivity to various antimalarial drugs14.
Pladmodium falciparum in the eastern border with Cam-
bodia is highly resistant to multi-antimalarial drugs while
P. falciparum in the southern border with Malaysia is the
most sensitive. Plasmodium vivax in different parts of the
country in this study showed different sensitivity to chlo-
roquine. Patients in Chanthaburi infected with higher
parasitaemia compared to the other three provinces, and
the parasite clearance time was also the slowest. Plasmo-
dium vivax in Yala was the most sensitive. However, there
is no clear evidence of P. vivax resistance to chloroquine
Fig. 4: CQ and DCQ concentration of 24 uncomplicated vivax malaria
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in Chanthaburi.
We treated patients with recurrence of parasitaemia
with primaquine (PQ) 15 mg daily for 14 days in addition
to CQ 25 mg/kg. Although PQ has only limited blood sch-
izonticidal activity in the doses normally used to eliminate
hypnozoites of P. vivax and gametocytes of P. falciparum,
in combination with CQ it is more efficacious than CQ
alone for the treatment of CQ-resistant P. vivax15. In Thai-
land, patients infected with P. vivax treated in the Minis-
try of Public Health facilities receive both CQ and PQ
(usually 0.25 mg/kg/day for 14 days). This treatment regi-
men may have played a role in suppressing the appear-
ance and/or extension of CQ-resistant parasites in the
region.
In conclusion, our study combining in vivo efficacy
data and CQ/DCQ measurements suggests that, resistance
of P. vivax to chloroquine is emerging in Kanchanaburi
province, near the border of Myanmar. Chloroquine re-
mains the first-line drug for P. vivax infections in Thai-
land; regular monitoring is needed to detect further devel-
opment of parasite resistance in this area. The monitoring
is also needed in the other areas of the country where ma-
laria is endemic to estimate the level of burden across the
country.
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